Arrowhead Presents Positive Plozasiran Data in Renal/Hepatic Impairment and Pregnancy Case

What happened

Arrowhead presented new clinical data at the EAS Congress showing plozasiran does not require dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment, and a case report suggesting sustained triglyceride lowering through pregnancy after preconception exposure. This data bolsters the safety and convenience profile of plozasiran, potentially easing prescribing in broader patient populations and supporting the ongoing sHTG Phase 3 program. However, the news does not materially alter the near-term investment thesis, which hinges on REDEMPLO commercial net sales disclosure and the Q3 2026 sHTG topline readout. The company's financials still show revenue dominated by collaboration accounting, and the 15.0% PIK term loan remains a liability overhang. While the data is incrementally positive, it is not a catalyst for re-rating without proof of commercial uptake or Phase 3 success.

Implication

The new data reduces some safety uncertainty for plozasiran in special populations, which could support label expansion and physician adoption. However, the investment thesis remains dependent on two near-term catalysts: REDEMPLO generating disclosed product revenue and the sHTG Phase 3 delivering on schedule in Q3 2026. Until those catalysts materialize, the stock's valuation already discounts a smooth commercialization and expansion, leaving limited margin of safety. The positive data may provide a floor for sentiment, but it does not resolve the binary risk around the sHTG readout or the pace of REDEMPLO payer coverage. Position sizing should still reflect the 3-6 month re-assessment window and the potential for dilution or timeline slips.

Thesis delta

The investment thesis remains unchanged, centered on REDEMPLO commercial traction and the sHTG Phase 3 timeline. This data incrementally supports plozasiran's clinical profile but does not provide the decisive proof of commercialization or expansion needed to shift from WAIT to BUY. The core risks—disclosed net sales, sHTG timing, and expensive debt—are unaddressed.